An acronym* for objective measures of acute and/or adverse cardiovascular events–e.g., acute myocardial infarction, ischaemic stroke, coronary arterial occlusion, death, which are used to assess the effects of various interventions–e.g., rotablation, angioplasty, stenting or therapeutics–e.g., antiarrhythmics, statins, ACE inhibitors on outcomes, in the context of a clinical trial.
*Major acute coronary events, major adverse cardiac events, major adverse cardiovascular events.
Comment While it is a commonly used end point for cardiovascular research, MACE has no standard definition. Varying definitions of composite end points, such as MACE, can lead to substantially different results and conclusions. Therefore, the term MACE should not be used, and when composite study end points are desired, researchers should focus separately on safety and effectiveness outcomes, and construct separate composite end points to match these different clinical goals
J Am Coll Cardiol, 2008; 51:701-707, doi:10.1016/j.jacc.2007.10.034